Loading...
Loading...
Loading...
Loading...
No reviews have been added for this product.
MBL Life Sciences
| Product Specifications | |
| Application | FC |
| Reactivity | Human |
| Conjugation | PE |
| Immunogen | modified WT1 |
| Peptide Sequence | CYTWNQMNL |
| Class | Class I |
| Sequence Location | 235-243 |
| MHC Allele | A*24:02 |
| Documents & Links for Tetramer/PE - HLA-A*24:02 WT1 (mutant) (CYTWNQMNL) | |
| Datasheet | Tetramer/PE - HLA-A*24:02 WT1 (mutant) (CYTWNQMNL) Datasheet |
| Documents & Links for Tetramer/PE - HLA-A*24:02 WT1 (mutant) (CYTWNQMNL) | |
| Datasheet | Tetramer/PE - HLA-A*24:02 WT1 (mutant) (CYTWNQMNL) Datasheet |
| Citations for Tetramer/PE - HLA-A*24:02 WT1 (mutant) (CYTWNQMNL) – 14 Found |
| Saitoh, Anri; Narita, Miwako; Watanabe, Norihiro; Tochiki, Nozomi; Yamahira, Akie; Nakamura, Takeshi; Kaji, Masami; Masuko, Masayoshi; Furukawa, Tatsuo; Toba, Ken; Fuse, Ichiro; Aizawa, Yoshifusa; Takahashi, Masuhiro. WT1 peptide vaccination in a CML patient: induction of effective cytotoxic T lymphocytes and significance of peptide administration interval. Medical Oncology (Northwood, London, England). 2011;28(1):219-30. PubMed |
| Chiba, Yasuyoshi; Hashimoto, Naoya; Tsuboi, Akihiro; Oka, Yoshihiro; Murao, Ayako; Kinoshita, Manabu; Kagawa, Naoki; Oji, Yusuke; Hosen, Naoki; Nishida, Sumiyuki; Sugiyama, Haruo; Yoshimine, Toshiki. Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma. Japanese Journal Of Clinical Oncology. 2010;40(5):395-403. PubMed |
| Narita, Miwako; Masuko, Masayoshi; Kurasaki, Tohri; Kitajima, Toshiki; Takenouchi, Shoko; Saitoh, Anri; Watanabe, Norihiro; Furukawa, Tatsuo; Toba, Ken; Fuse, Ichiro; Aizawa, Yoshifusa; Kawakami, Manabu; Oka, Yoshihiro; Sugiyama, Haruo; Takahashi, Masuhiro. WT1 peptide vaccination in combination with imatinib therapy for a patient with CML in the chronic phase. International Journal Of Medical Sciences. 2010;7(2):72-81. PubMed |
| Tsuboi, Akihiro; Oka, Yoshihiro; Nakajima, Hiroko; Fukuda, Yoko; Elisseeva, Olga A; Yoshihara, Satoshi; Hosen, Naoki; Ogata, Atsushi; Kito, Katsuyuki; Fujiki, Fumihiro; Nishida, Sumiyuki; Shirakata, Toshiaki; Ohno, Satoshi; Yasukawa, Masaki; Oji, Yusuke; Kawakami, Manabu; Morita, Satoshi; Sakamoto, Junichi; Udaka, Keiko; Kawase, Ichiro; Sugiyama, Haruo. Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. International Journal Of Hematology. 2007;86(5):414-7. PubMed |
| Najima, Yuho; Tomizawa-Murasawa, Mariko; Saito, Yoriko; Watanabe, Takashi; Ono, Rintaro; Ochi, Toshiki; Suzuki, Nahoko; Fujiwara, Hiroshi; Ohara, Osamu; Shultz, Leonard D; Yasukawa, Masaki; Ishikawa, Fumihiko. Induction of WT1-specific human CD8+ T cells from human HSCs in HLA class I Tg NOD/SCID/IL2rgKO mice. Blood. 2016;127(6):722-34. PubMed |
| Nishida, Sumiyuki; Ishikawa, Takeshi; Egawa, Shinichi; Koido, Shigeo; Yanagimoto, Hiroaki; Ishii, Jun; Kanno, Yoshihide; Kokura, Satoshi; Yasuda, Hiroaki; Oba, Mari Saito; Sato, Maho; Morimoto, Soyoko; Fujiki, Fumihiro; Eguchi, Hidetoshi; Nagano, Hiroaki; Kumanogoh, Atsushi; Unno, Michiaki; Kon, Masanori; Shimada, Hideaki; Ito, Kei; Homma, Sadamu; Oka, Yoshihiro; Morita, Satoshi; Sugiyama, Haruo. Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study. Cancer Immunology Research. 2018;6(3):320-331. PubMed |
| Yanagisawa, Ryu; Koizumi, Tomonobu; Koya, Terutsugu; Sano, Kenji; Koido, Shigeo; Nagai, Kazuhiro; Kobayashi, Masanori; Okamoto, Masato; Sugiyama, Haruo; Shimodaira, Shigetaka. WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study. Anticancer Research. 2018;38(4):2217-2225. PubMed |
| Matsuda, Tatsuo; Takeuchi, Hiroya; Sakurai, Toshiharu; Mayanagi, Shuhei; Booka, Eisuke; Fujita, Tomonobu; Higuchi, Hajime; Taguchi, Junichi; Hamamoto, Yasuo; Takaishi, Hiromasa; Kawakubo, Hirofumi; Okamoto, Masato; Sunamura, Makoto; Kawakami, Yutaka; Kitagawa, Yuko. Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer. Oncology Letters. 2018;16(1):1348-1356. PubMed |
| Watanabe, Kazue; Tsukahara, Tomohide; Toji, Shingo; Saitoh, Shogo; Hirohashi, Yoshihiko; Nakatsugawa, Munehide; Kubo, Terufumi; Kanaseki, Takayuki; Kameshima, Hidekazu; Terui, Takeshi; Sato, Noriyuki; Torigoe, Toshihiko. Development of a T-cell receptor multimer with high avidity for detecting a naturally presented tumor-associated antigen on osteosarcoma cells. Cancer Science. 2019;110(1):40-51. PubMed |
| Morimoto, Soyoko; Fujiki, Fumihiro; Kondo, Kenta; Nakajima, Hiroko; Kobayashi, Yoshiki; Inatome, Miki; Aoyama, Nao; Nishida, Yuya; Tsuboi, Akihiro; Oka, Yoshihiro; Nishida, Sumiyuki; Nakata, Jun; Hosen, Naoki; Oji, Yusuke; Sugiyama, Haruo. Establishment of a novel platform cell line for efficient and precise evaluation of T cell receptor functional avidity. Oncotarget. 2018;9(75):34132-34141. PubMed |
| Zhang, Wen; Lu, Xu; Cui, Peilin; Piao, Chunmei; Xiao, Man; Liu, Xuesong; Wang, Yue; Wu, Xuan; Liu, Jingwei; Yang, Lin. Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer. Cancer Immunology, Immunotherapy : Cii. 2019;68(1):121-130. PubMed |
| Tsuboi, Akihiro; Hashimoto, Naoya; Fujiki, Fumihiro; Morimoto, Soyoko; Kagawa, Naoki; Nakajima, Hiroko; Hosen, Naoki; Nishida, Sumiyuki; Nakata, Jun; Morita, Satoshi; Sakamoto, Junichi; Oji, Yusuke; Oka, Yoshihiro; Sugiyama, Haruo. A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma. Cancer Immunology, Immunotherapy : Cii. 2019;68(2):331-340. PubMed |
| Nishida, Sumiyuki; Tsuboi, Akihiro; Tanemura, Atsushi; Ito, Toshinori; Nakajima, Hiroko; Shirakata, Toshiaki; Morimoto, Soyoko; Fujiki, Fumihiro; Hosen, Naoki; Oji, Yusuke; Kumanogoh, Atsushi; Kawase, Ichiro; Oka, Yoshihiro; Azuma, Ichiro; Morita, Satoshi; Sugiyama, Haruo. Immune adjuvant therapy using Bacillus Calmette-Guérin cell wall skeleton (BCG-CWS) in advanced malignancies: A phase 1 study of safety and immunogenicity assessments. Medicine. 2019;98(33):e16771. PubMed |
| Nagai, Kazuhiro; Adachi, Tomohiko; Harada, Hiroshi; Eguchi, Susumu; Sugiyama, Haruo; Miyazaki, Yasushi. Dendritic Cell-based Immunotherapy Pulsed With Wilms Tumor 1 Peptide and Mucin 1 as an Adjuvant Therapy for Pancreatic Ductal Adenocarcinoma After Curative Resection: A Phase I/IIa Clinical Trial. Anticancer Research. 2020;40(10):5765-5776. PubMed |
MBL Life Sciences
| Product Specifications | |
| Application | FC |
| Reactivity | Human |
| Conjugation | PE |
| Immunogen | modified WT1 |
| Peptide Sequence | CYTWNQMNL |
| Class | Class I |
| Sequence Location | 235-243 |
| MHC Allele | A*24:02 |
| Documents & Links for Tetramer/PE - HLA-A*24:02 WT1 (mutant) (CYTWNQMNL) | |
| Datasheet | Tetramer/PE - HLA-A*24:02 WT1 (mutant) (CYTWNQMNL) Datasheet |
| Documents & Links for Tetramer/PE - HLA-A*24:02 WT1 (mutant) (CYTWNQMNL) | |
| Datasheet | Tetramer/PE - HLA-A*24:02 WT1 (mutant) (CYTWNQMNL) Datasheet |
| Citations for Tetramer/PE - HLA-A*24:02 WT1 (mutant) (CYTWNQMNL) – 14 Found |
| Saitoh, Anri; Narita, Miwako; Watanabe, Norihiro; Tochiki, Nozomi; Yamahira, Akie; Nakamura, Takeshi; Kaji, Masami; Masuko, Masayoshi; Furukawa, Tatsuo; Toba, Ken; Fuse, Ichiro; Aizawa, Yoshifusa; Takahashi, Masuhiro. WT1 peptide vaccination in a CML patient: induction of effective cytotoxic T lymphocytes and significance of peptide administration interval. Medical Oncology (Northwood, London, England). 2011;28(1):219-30. PubMed |
| Chiba, Yasuyoshi; Hashimoto, Naoya; Tsuboi, Akihiro; Oka, Yoshihiro; Murao, Ayako; Kinoshita, Manabu; Kagawa, Naoki; Oji, Yusuke; Hosen, Naoki; Nishida, Sumiyuki; Sugiyama, Haruo; Yoshimine, Toshiki. Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma. Japanese Journal Of Clinical Oncology. 2010;40(5):395-403. PubMed |
| Narita, Miwako; Masuko, Masayoshi; Kurasaki, Tohri; Kitajima, Toshiki; Takenouchi, Shoko; Saitoh, Anri; Watanabe, Norihiro; Furukawa, Tatsuo; Toba, Ken; Fuse, Ichiro; Aizawa, Yoshifusa; Kawakami, Manabu; Oka, Yoshihiro; Sugiyama, Haruo; Takahashi, Masuhiro. WT1 peptide vaccination in combination with imatinib therapy for a patient with CML in the chronic phase. International Journal Of Medical Sciences. 2010;7(2):72-81. PubMed |
| Tsuboi, Akihiro; Oka, Yoshihiro; Nakajima, Hiroko; Fukuda, Yoko; Elisseeva, Olga A; Yoshihara, Satoshi; Hosen, Naoki; Ogata, Atsushi; Kito, Katsuyuki; Fujiki, Fumihiro; Nishida, Sumiyuki; Shirakata, Toshiaki; Ohno, Satoshi; Yasukawa, Masaki; Oji, Yusuke; Kawakami, Manabu; Morita, Satoshi; Sakamoto, Junichi; Udaka, Keiko; Kawase, Ichiro; Sugiyama, Haruo. Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. International Journal Of Hematology. 2007;86(5):414-7. PubMed |
| Najima, Yuho; Tomizawa-Murasawa, Mariko; Saito, Yoriko; Watanabe, Takashi; Ono, Rintaro; Ochi, Toshiki; Suzuki, Nahoko; Fujiwara, Hiroshi; Ohara, Osamu; Shultz, Leonard D; Yasukawa, Masaki; Ishikawa, Fumihiko. Induction of WT1-specific human CD8+ T cells from human HSCs in HLA class I Tg NOD/SCID/IL2rgKO mice. Blood. 2016;127(6):722-34. PubMed |
| Nishida, Sumiyuki; Ishikawa, Takeshi; Egawa, Shinichi; Koido, Shigeo; Yanagimoto, Hiroaki; Ishii, Jun; Kanno, Yoshihide; Kokura, Satoshi; Yasuda, Hiroaki; Oba, Mari Saito; Sato, Maho; Morimoto, Soyoko; Fujiki, Fumihiro; Eguchi, Hidetoshi; Nagano, Hiroaki; Kumanogoh, Atsushi; Unno, Michiaki; Kon, Masanori; Shimada, Hideaki; Ito, Kei; Homma, Sadamu; Oka, Yoshihiro; Morita, Satoshi; Sugiyama, Haruo. Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study. Cancer Immunology Research. 2018;6(3):320-331. PubMed |
| Yanagisawa, Ryu; Koizumi, Tomonobu; Koya, Terutsugu; Sano, Kenji; Koido, Shigeo; Nagai, Kazuhiro; Kobayashi, Masanori; Okamoto, Masato; Sugiyama, Haruo; Shimodaira, Shigetaka. WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study. Anticancer Research. 2018;38(4):2217-2225. PubMed |
| Matsuda, Tatsuo; Takeuchi, Hiroya; Sakurai, Toshiharu; Mayanagi, Shuhei; Booka, Eisuke; Fujita, Tomonobu; Higuchi, Hajime; Taguchi, Junichi; Hamamoto, Yasuo; Takaishi, Hiromasa; Kawakubo, Hirofumi; Okamoto, Masato; Sunamura, Makoto; Kawakami, Yutaka; Kitagawa, Yuko. Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer. Oncology Letters. 2018;16(1):1348-1356. PubMed |
| Watanabe, Kazue; Tsukahara, Tomohide; Toji, Shingo; Saitoh, Shogo; Hirohashi, Yoshihiko; Nakatsugawa, Munehide; Kubo, Terufumi; Kanaseki, Takayuki; Kameshima, Hidekazu; Terui, Takeshi; Sato, Noriyuki; Torigoe, Toshihiko. Development of a T-cell receptor multimer with high avidity for detecting a naturally presented tumor-associated antigen on osteosarcoma cells. Cancer Science. 2019;110(1):40-51. PubMed |
| Morimoto, Soyoko; Fujiki, Fumihiro; Kondo, Kenta; Nakajima, Hiroko; Kobayashi, Yoshiki; Inatome, Miki; Aoyama, Nao; Nishida, Yuya; Tsuboi, Akihiro; Oka, Yoshihiro; Nishida, Sumiyuki; Nakata, Jun; Hosen, Naoki; Oji, Yusuke; Sugiyama, Haruo. Establishment of a novel platform cell line for efficient and precise evaluation of T cell receptor functional avidity. Oncotarget. 2018;9(75):34132-34141. PubMed |
| Zhang, Wen; Lu, Xu; Cui, Peilin; Piao, Chunmei; Xiao, Man; Liu, Xuesong; Wang, Yue; Wu, Xuan; Liu, Jingwei; Yang, Lin. Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer. Cancer Immunology, Immunotherapy : Cii. 2019;68(1):121-130. PubMed |
| Tsuboi, Akihiro; Hashimoto, Naoya; Fujiki, Fumihiro; Morimoto, Soyoko; Kagawa, Naoki; Nakajima, Hiroko; Hosen, Naoki; Nishida, Sumiyuki; Nakata, Jun; Morita, Satoshi; Sakamoto, Junichi; Oji, Yusuke; Oka, Yoshihiro; Sugiyama, Haruo. A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma. Cancer Immunology, Immunotherapy : Cii. 2019;68(2):331-340. PubMed |
| Nishida, Sumiyuki; Tsuboi, Akihiro; Tanemura, Atsushi; Ito, Toshinori; Nakajima, Hiroko; Shirakata, Toshiaki; Morimoto, Soyoko; Fujiki, Fumihiro; Hosen, Naoki; Oji, Yusuke; Kumanogoh, Atsushi; Kawase, Ichiro; Oka, Yoshihiro; Azuma, Ichiro; Morita, Satoshi; Sugiyama, Haruo. Immune adjuvant therapy using Bacillus Calmette-Guérin cell wall skeleton (BCG-CWS) in advanced malignancies: A phase 1 study of safety and immunogenicity assessments. Medicine. 2019;98(33):e16771. PubMed |
| Nagai, Kazuhiro; Adachi, Tomohiko; Harada, Hiroshi; Eguchi, Susumu; Sugiyama, Haruo; Miyazaki, Yasushi. Dendritic Cell-based Immunotherapy Pulsed With Wilms Tumor 1 Peptide and Mucin 1 as an Adjuvant Therapy for Pancreatic Ductal Adenocarcinoma After Curative Resection: A Phase I/IIa Clinical Trial. Anticancer Research. 2020;40(10):5765-5776. PubMed |
